Pliant Therapeutics (NASDAQ:PLRX) versus EOM Pharmaceuticals (OTCMKTS:IMUC) Head to Head Analysis

Pliant Therapeutics (NASDAQ:PLRX) and EOM Pharmaceuticals (OTCMKTS:IMUC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Institutional & Insider Ownership

97.3% of Pliant Therapeutics shares are held by institutional investors. 6.4% of Pliant Therapeutics shares are held by insiders. Comparatively, 3.3% of EOM Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Pliant Therapeutics and EOM Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	0	0	7	1	3.13
EOM Pharmaceuticals	0	0	0	0	0.00

Pliant Therapeutics currently has a consensus target price of $40.50, suggesting a potential upside of 261.28%. Given Pliant Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Pliant Therapeutics is more favorable than EOM Pharmaceuticals.

Earnings and Valuation

This table compares Pliant Therapeutics and EOM Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58 million	431.73	-$161.34 million	($3.34)	-3.36
EOM Pharmaceuticals	N/A	N/A	-$1.61 million	N/A	N/A

EOM Pharmaceuticals has lower revenue, but higher earnings than Pliant Therapeutics.

Volatility and Risk

Pliant Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, EOM Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Profitability

This table compares Pliant Therapeutics and EOM Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-48.91%	-41.09%
EOM Pharmaceuticals	N/A	N/A	N/A

Summary

Pliant Therapeutics beats EOM Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Pliant Therapeutics

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

About EOM Pharmaceuticals

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.